This will then lead to an abnormalamount of bone resorption, creating an empty cavity that the ameloblastoma tumourcan grow into.12 The RANKL antibody denosumab has been used efficiently in gianttumour cells to inhibit osteoclast activation in vitro .13 Since theRANKL pathway may be significantly involved in ameloblastoma invasion, drugsneutralising this ligand are promising candidates to be used for treatment. The gene discussed is TNFSF11; the disease is ameloblastoma.